IDH1 and glioma: In other tumors, it was found that the efficacy of Ivosidenib targeting IDH was significant (NCT02074839, NCT02677922).78–81 Ivosidenib showed good tolerability and efficacy in patients with recurrent or progressive IDH-must gliomas (NCT02073994).82 In addition, a vaccine targeting the IDH1 (R132H) mutation showed good tolerability with a high pseudo-progression rate for newly-diagnosed grade 3–4 gliomas (NCT02454634).83 Due to successful attempts in other tumors, many clinical trials targeting IDH mut gliomas are being initiated (NCT02771301, NCT04906473).